Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 3
1981 1
1982 2
1983 7
1984 14
1985 21
1986 33
1987 34
1988 26
1989 43
1990 35
1991 44
1992 39
1993 58
1994 37
1995 48
1996 86
1997 101
1998 79
1999 98
2000 90
2001 82
2002 97
2003 95
2004 91
2005 75
2006 59
2007 72
2008 76
2009 75
2010 87
2011 77
2012 82
2013 78
2014 96
2015 78
2016 61
2017 92
2018 80
2019 84
2020 90
2021 92
2022 78
2023 66
2024 70
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,626 results

Results by year

Filters applied: . Clear all
Page 1
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Gohring G, Behrens YL, Li Z, Dallmann LK, Klement P, Albert C, Wichmann M, Alwie Y, Benner A, Saadati M, Ganser A, Thol F, Heuser M. Shahswar R, et al. Haematologica. 2024 Jan 1;109(1):72-83. doi: 10.3324/haematol.2023.282912. Haematologica. 2024. PMID: 37470150 Free PMC article.
This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or with venetoclax (FLAVIDA) in patients with R/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venet …
This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or with ven …
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
Overall survival rates at 5 years were 48% for the daunorubicin group and 48% for the idarubicin group (P = .54), and relapse-free survival rates at 5 years were 41% and 41% (P = .97), respectively. Thus, high-dose daunorubicin and standard-dose idarubicin were equa …
Overall survival rates at 5 years were 48% for the daunorubicin group and 48% for the idarubicin group (P = .54), and relapse-free su …
Idarubicin.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Jul;7(3):117-20. doi: 10.1177/104345429000700307. J Pediatr Oncol Nurs. 1990. PMID: 2206474 No abstract available.
Idarubicin.
Crivellari D, Toffoli G, Lombardi D, Berretta M, Sorio R, Magri MD, Spazzapan S, Scuderi C, Veronesi A. Crivellari D, et al. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S73-4. doi: 10.1177/030089160208800122. Tumori. 2002. PMID: 11989932 No abstract available.
Is Idarubicin the Future of TACE?
Padia SA. Padia SA. Radiology. 2019 Jun;291(3):809-810. doi: 10.1148/radiol.2019190789. Epub 2019 Apr 30. Radiology. 2019. PMID: 31039076 No abstract available.
Idarubicin: an anthracycline antineoplastic agent.
Cersosimo RJ. Cersosimo RJ. Clin Pharm. 1992 Feb;11(2):152-67. Clin Pharm. 1992. PMID: 1551297 Review.
The mechanism of action, pharmacokinetics, activity, adverse effects, and administration of idarubicin are reviewed. Idarubicin is currently approved for use with other agents in the management of acute nonlymphocytic leukemia in adults. ...Idarubicin is at l …
The mechanism of action, pharmacokinetics, activity, adverse effects, and administration of idarubicin are reviewed. Idarubicin …
Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM, Berman E, Maraone MP, Ganzina F. Carella AM, et al. Haematologica. 1990 Mar-Apr;75(2):159-69. Haematologica. 1990. PMID: 2192943 Review.
Its antileukemic activity in preclinical models prompted the introduction of Idarubicin into clinical studies. As a single agent, Idarubicin produced complete remission in 20% and 30% of patients with heavily pretreated pediatric and adult acute myeloid leukemia (AM …
Its antileukemic activity in preclinical models prompted the introduction of Idarubicin into clinical studies. As a single agent, …
Idarubicin: a second-generation anthracycline.
Fields SM, Koeller JM. Fields SM, et al. DICP. 1991 May;25(5):505-17. doi: 10.1177/106002809102500511. DICP. 1991. PMID: 2068836 Review.
Idarubicin also has the advantage of oral administration, but the oral formulation of the drug remains investigational. The use of idarubicin in pediatric patients also remains to be established....
Idarubicin also has the advantage of oral administration, but the oral formulation of the drug remains investigational. The use of …
Clinical pharmacokinetics of idarubicin.
Robert J. Robert J. Clin Pharmacokinet. 1993 Apr;24(4):275-88. doi: 10.2165/00003088-199324040-00002. Clin Pharmacokinet. 1993. PMID: 8491056 Review.
The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%. ...About 10% of the injected dose is recovered in urine as idarubicin and idarubicinol, and only slightly higher proportions are r …
The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40 …
Oral idarubicin--an anthracycline derivative with unique properties.
Goebel M. Goebel M. Ann Hematol. 1993 Jan;66(1):33-43. doi: 10.1007/BF01737687. Ann Hematol. 1993. PMID: 8431520 Review.
Idarubicin belongs to a group of anthracyclines in which the methoxyl group in position 4 of the D ring in the aglycone moiety is replaced by a hydrogen atom. ...Preclinical and clinical experiences with oral idarubicin are reviewed....
Idarubicin belongs to a group of anthracyclines in which the methoxyl group in position 4 of the D ring in the aglycone moiety is rep …
2,626 results

Searches related to "idarubicin"